Cognitive Augmentation, Remediation, and TDCS for Schizophrenia (CARTS)
Cognitive Augmentation, Remediation, and TDCS for Schizophrenia (CARTS)
Schizophrenia-spectrum disorders (SSDs; schizophrenia, schizoaffective disorder, etc.) are among the most disabling and costly conditions globally. Most SSD medications treat symptoms like hallucinations and delusions, but cognitive symptoms, or problems with thinking, memory, and problem solving, remain untreated by medication. Other developing treatments for these symptoms include noninvasive stimulation of cognitive brain regions and behavioral therapies involving mental skill-building activities. While both of these treatments appear to improve cognitive symptoms, effects are inconsistent depending on specific details of the trial. Growing evidence suggests that using these therapies together could lead to larger, clinically meaningful effects. Still, prior combined therapy trials use simplified versions of the behavioral therapy, omitting the guidance of a therapist to engage and challenge the participant. These previous trials show some evidence for beneficial effects, particularly in working memory, but the omission of a therapist could limit effects. This study will be the first to test if using a comprehensive, therapist-guided behavioral therapy can amplify the effects of noninvasive brain stimulation (NIBS) to reduce cognitive symptoms and change brain activity in SSDs. We will conduct a small pilot study to gather preliminary evidence for this combined therapy using 10 participants split into 2 groups. One group will receive NIBS and comprehensive cognitive therapy (NIBS+) while the other receives NIBS and performs quizzes without the guidance of a therapist (NIBS-). Participants will receive therapies for 10 days over 2 weeks with 2 hours of therapy per day. We will compare interventions through the following aims. Aim 1 will examine changes in brain connections after NIBS+ and NIBS-. We will collect data from electrical brain recordings (electroencephalography/EEG) before and after interventions. We expect that connections between cognitive brain regions will be most strengthened by NIBS+ compared to NIBS-. Aim 2 will investigate what kind of cognitive symptoms are affected by NIBS+ and NIBS-. We will perform cognitive tests before and after the interventions. We expect that all cognitive symptoms (memory, motor speed, language skills, attention, processing speed, and planning abilities) will be most improved by NIBS+ compared to NIBS-, but that the largest improvements will be in short-term, active memory skills ("working memory"). We will also investigate if there is a relationship between the changes in brain connections and cognitive improvements.
This preliminary study will provide early evidence that the effects of noninvasive brain stimulation can be strengthened by a structured, therapist-guided behavioral therapy for cognitive symptoms. This will support the development of a new, combined therapy for untreated cognitive symptoms in schizophrenia-spectrum disorders. We will use findings of this study to support a trial proposal to the National Institute of Mental Health to test this therapy in a larger group of individuals.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Rebekah L Trotti, PhD
- Phone Number: 617-754-1262
- Email: rtrotti@bidmc.harvard.edu
Study Contact Backup
- Name: Brendan Stiltner, BS
- Email: bstiltne@bidmc.harvard.edu
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Beth Israel Deaconess Medical Center
-
Contact:
- Rebekah L Trotti, PhD
- Phone Number: 617-754-1262
- Email: rtrotti@bidmc.harvard.edu
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of schizophrenia, schizoaffective disorder, or schizophreniform disorder
- Proficient in English
- IQ >= 80
Exclusion Criteria:
- Major neurological conditions
- Implanted devices in the body or metal in the head
- Changes to relevant medications within 1 month of enrollment
- Pregnancy or breastfeeding
- Moderate to severe DSM V substance use disorder
- Clinical instability including recent or severe suicidal ideation or actions
- Positive urine drug screen for illicit substances
- Skin allergy to lidocaine or electrolyte gel
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: NIBS+
Combined transcranial direct current stimulation and cognitive remediation therapy (both active) |
Active HD-tDCS delivered to the left dorsolateral prefrontal cortex
Other Names:
Active cognitive remediation therapy. Cognitive exercises are delivered with NeuropsychOnline and administered by a trained coach.
Other Names:
|
|
Active Comparator: NIBS-
Transcranial direct current stimulation and sham cognitive remediation therapy (active tDCS and sham CRT) |
Active HD-tDCS delivered to the left dorsolateral prefrontal cortex
Other Names:
An active comparator for cognitive remediation therapy, delivered with quizzes collected from Sporcle.com.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Functional connectivity with the prefrontal cortex
Time Frame: Pre-intervention to post-intervention at 2-weeks
|
Participants will be directed to keep their eyes open and loosely fixed on a plus sign on the screen in front of them for 5 minutes while EEG is recorded. Resting data will be cleaned, processed, and transformed to 4 frequency band values: delta/theta, alpha, beta, and gamma. Frequency data will be converted to connectivity values using weighted phase lag index (wPLI). Average connectivity of all sensors with the prefrontal sensor F3 will be calculated and compared between timepoints. |
Pre-intervention to post-intervention at 2-weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Brief Assessment of Cognition Digit Sequencing (Working Memory)
Time Frame: Pre-intervention to post-intervention at 2-weeks
|
Participants will arrange random number strings in ascending order during the Brief Assessment of Cognition. This score, which indexes working memory is called Digit Sequencing and will be z-scored according to published norms and compared between timepoints. |
Pre-intervention to post-intervention at 2-weeks
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Brief Assessment of Cognition subdomains
Time Frame: Pre-intervention to post-intervention at 2-weeks
|
Participants will complete the Brief Assessment of Cognition, which includes tasks indexing psychomotor and visual processing speed, lexical access, attention and processing speed, and executive functioning, called Token Motor, Verbal Fluency, Symbol Coding, and Tower of London, respectively. These subdomain scores will be normed and compared between timepoints. |
Pre-intervention to post-intervention at 2-weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2026P000528
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Only IPD used in the results publication will be shared.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.